ImmunAdd Inc.

Startup

Found in 2022, ImmunAdd is a privately held biotech pharmaceutical company focused on the design of vaccine adjuvant and formulation development of vaccines. Our team members have accumulated years of experience in medicinal chemistry, drug formulation, drug regulations, biological animal evaluations, and clinical trials. QS-21, a golden standard saponin adjuvant, has been approved by the FDA in the formulation of shingle vaccine, malaria vaccine, RSV vaccine, and Covid vaccine. With the promising immune responses in vaccines, Quillaja harvesting might be unsustainable. Our innovative saponin-based adjuvant IA-05 represents a refined QS-21 analog. IA-05 exhibits enhanced tolerability, stability, and the ability to elicit long-term immune responses when combined with viral and bacterial vaccines. One of the key advantages of IA-05 is its cost-effective, large-scale manufacturing process, which eliminates the need for Quillaja harvesting. With saponin adjuvant IA-05 in hand, ImmunAdd further develops AS01-like formulation. Combining IA-05 and toll-like receptor 4 agonist, IAS-01 outperforms humoral and cellular immunity in a variety of vaccines. Currently, IAS-01 is GMP production with DMF, and we hope to establish strategic partnerships with vaccine companies to enhance the efficacy of vaccines. We look forward to outstanding adjuvant systems collaborating with vaccine companies to create more value for human health.

website